Heart Valve Stenosis Segment to Lead Global Structural Heart Market During 2022–2028

According to our latest study on "Structural Heart Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Procedure, and End User," the market was valued at US$ 14,245.55 million in 2022 and is expected to reach US$ 22,560.88 million by 2028; it is estimated to record a CAGR of 8.0% from 2022 to 2028. The report highlights the key factors driving the market growth, prominent players with their developments in the market, and trends prevailing in the market.

Structural heart disease is a non-coronary defect of the heart, thus not affecting the blood vessels in the heart. Most structural heart conditions are present since birth (congenital), but these can also be acquired later in life owing to wear & tear from infection. Advancements in the medical field have replaced open-heart surgical procedures with minimally invasive procedures. The devices that are used in structural heart disease comprise replacement and repair devices, such as devices that are used for the treatment of heart-related diseases. Structural heart devices comprise annuloplasty rings and heart valve balloons occluders, among others. These devices are used to reshape and tighten the ring around the heart in case the heart is enlarged or has a leaky valve. Availability of innovative structural heart services and rise in the number of cardiovascular diseases and training programs are the key factors driving the structural heart market growth. However, the high cost of procedures followed by stringent regulations regarding structural heart devices are hampering the growth of the structural heart market.

Based on procedure, the global structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. In 2022, the heart valve stenosis segment held the largest share and anticipated to register the highest CAGR during the forecast period. Heart valve stenosis is a valvular heart condition where the heart valve is narrowed or not able to open completely. This reduces the blood flow from the heart to rest of the body, which creates pressure on the heart. These procedures are performed either traditionally as open-heart procedures or as minimally invasive procedures that help in faster recovery. Transcatheter aortic valve replacement is one of the advanced minimally invasive procedures for the treatment of aortic stenosis. Additionally, there has been an increase in training programs and conferences on a global level for such procedures. Therefore, such factors are expected to boost the structural heart market for the segment during the forecast period.

Impact of COVID-19 Pandemic on Global Structural Heart Market

The COVID-19 pandemic had a huge impact on the regions across the globe as it tested the resilience of economies and placed immense pressure on health workers. A socio-economic analysis of the impact of the pandemic by the United Nations Development Programme (UNDP) helped governments of various countries overhaul policies and invest in public health, economic stimulus, and social safety. These measures helped countries recover faster from the adversities caused by the COVID-19 crisis. Governments of various countries ensured the uninterrupted availability of life-supporting medical equipment. The COVID-19 pandemic altered economic conditions and social behaviors in North American countries. Containment measures enacted by the US government to mitigate the spread of SARS-CoV-2 changed the pattern of healthcare service delivery in the country. According to the Department of Emergency Medicine, in many cities across the US, emergency department (ED) visits decreased by ~40% in 2020. According to a study titled “Impact of COVID-19 on Management Strategies for Coronary and Structural Heart Disease Interventions,” in 2022, 77 patients were scheduled for TAVR at a tertiary center in the US, and 28.6% of cases were canceled because of the pandemic. The decisions about the timing of SHD interventions considered the risk of delaying the procedure, exposure to COVID-19, and use of limited hospital resources. In the surgical field, hospitals across the country restricted performing elective surgeries, including surgical aortic valve replacement (SAVR), to conserve ventilators, operating rooms, and intensive care unit beds. The structural heart market had witnessed a shortfall at the beginning of the COVID-19 crisis owing to factors such as disruption in supply chain and demand due to the lockdown announced by the majority of European countries that caused disruptions in manufacturing and supply chain operations. Additionally, appointments have been delayed in many clinics owing to the rising number of cases. However, with the implementation of proper guidelines and protocols to reduce SARS-CoV-2 exposure to patients during their visits, the hospitals have begun to continue their CVD operations and adapt their appointment schedules based on local cases of COVID-19. Therefore, there was a short-term impact of the COVID-19 pandemic on the global structural heart market.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc., Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomédica Industry, Commerce and Representations Ltd, Aran Biomedical Teoranta, Micro Interventional Devices Inc, and Corcym UK Ltd. are among the leading companies operating in the global structural heart market.

The report segments the global structural heart market as follows:

The global structural heart market is segmented on the basis of product, procedure, end user, and geography. Based on product, the structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. Based on procedure, the structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. Based on end user, the structural heart market is segmented into hospitals, ambulatory surgical centers, and cardiac centers. Based on geography, the structural heart market is segmented into North America (US, Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), South & Central America (Brazil, Argentina, and Rest of South & Central America), and Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com